What Кортексин treats: Main Uses and Benefits

The primary therapeutic use of Кортексин is to provide supportive benefit across several domains of central nervous system function, generally in clinical settings marked by compromised cerebral capacity. Its use is associated with symptomatic management across therapeutic areas involving supportive neurofunctional care.

The medication is commonly applied across conditions presenting with acute episodes and recurrent manifestations, including the acute period of ischemic stroke, the consequences of Traumatic Brain Injury (TBI), and chronic dyscirculatory encephalopathy. It is also considered relevant for easing symptoms in pediatric contexts, such as those related to developmental speech delay and perinatal CNS lesions.

The supportive therapy is relevant for easing symptoms and contributes to improved day-to-day comfort during symptomatic periods. One aspect of its therapeutic profile indicates:

“The application is relevant when supportive symptom management is appropriate and may assist with easing the overall symptom load.”

It is generally used to address symptom clusters that may become intense or disruptive, particularly Intellectual-Mnestic Dysfunctions (impaired attention and memory) and generalized symptoms like asthenoneurotic syndrome (chronic mental fatigue).

---

Quick Fact: Supportive management for Asthenia and Cognitive Strain

Who Can and Cannot Use Кортексин?

The official eligibility profile for Кортексин (Cortexin) is defined by regulatory authorities based on established use and absolute contraindications.

Contraindicated Populations

Use of this medicine is strictly prohibited in the following groups, based on official prescribing information:

• Hypersensitivity: Individuals with a known individual intolerance to the polypeptide components or any part of the drug.
• Pregnancy: Women who are pregnant must not use the medicine.
• Lactation (Breastfeeding): Use is contraindicated; breastfeeding must be immediately discontinued if the medicine is required.

Note that the prohibition during pregnancy and lactation is explicitly due to the absence of clinical research data for these populations, as stated by regulatory bodies.

Established Eligibility and Restrictions

Population Group	Regulatory Status
Adults	Established use is permitted under standard labeled conditions.
Children & Adolescents	Established use is permitted for approved indications.
Pediatric Restriction	Use in children is subject to a weight-based condition, necessitating dosage adjustment based on whether the child weighs less than or more than 20 kg.
Organ Impairment	The official label does not document specific contraindications or limitations based on renal or hepatic impairment.

Interactions with other medicines and products

Pharmacological Interaction Profile

Official regulatory documents indicate that the medicine Кортексин does not exhibit significant pharmacological interaction patterns with other medicinal products. The drug is defined by its lack of documented metabolic conflicts, meaning there are no officially stated interactions related to Cytochrome P450 enzymes, drug transporters, or other specific pharmacokinetic pathways. The official labeling states that it may be included as a component in complex therapeutic regimens without concern for typical drug-drug conflicts.

Restrictions on Administration and Preparation

Despite the absence of significant pharmacological interactions, the official regulatory information details specific physical and procedural restrictions that govern its administration:

• Physical Incompatibility: The prepared solution of the lyophilisate must not be mixed with other medicinal products or solutions. This necessitates that the medicine must be administered separately from other injectable medications, which functions as a mandatory timing rule.
• Population-Specific Solvent Restriction: A specific constraint applies to reconstitution in the pediatric population. The use of Lidocaine (Procaine) as a solvent is not recommended in children. This restriction is documented because using Lidocaine for reconstitution in this population is officially associated with an increased severity of adverse reactions.

No official regulatory data documents specific interactions with food, alcohol, herbal products, or dietary supplements.

Кортексин, a polypeptide complex, is observed to cross the blood-brain barrier and demonstrates selective accumulation in cortical neurons.

Molecular and Intracellular Pathways

The constituent peptides exhibit multitargeted interactions with various neuronal receptors and enzymes. Specifically, in vitro binding assays indicate interaction with AMPA and kainate receptors, acting as non-competitive binders/modulators of glutamatergic signaling. It also interacts with GABAA1 and metabotropic glutamate receptors (mGluR1, mGluR5), thus modulating both excitatory and inhibitory neurotransmission.

Intracellularly, it engages in anti-apoptotic signaling by inhibiting caspase-8 activity, which reduces the cascade leading to programmed cell death. The drug also modulates mitochondrial function by stabilizing the mitochondrial membrane potential (Delta Psim) and initiating the restoration of ATP synthesis within nerve cells. Furthermore, Кортексин influences gene expression of neurotrophic factors, including Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF), leading to increased neuronal plasticity.

System-Level Physiological Consequences

These molecular effects result in system-level neuroprotection and neurotrophic modulation, contributing to the overall stabilization of neuronal functional integrity and modulation of synaptic efficacy within the central nervous system.

Official Administration Guidelines for Кортексин

Кортексин (Cortexin) is a lyophilized powder for solution and is intended exclusively for parenteral administration. This injectable medication must be prepared and administered strictly according to the prescribing physician's instructions and the official product leaflet.

---

Administration Scope

Feature	Official Requirement
Route of administration	Intramuscular (IM) injection is the only route of administration currently registered for routine use.
Preparation requirements	The lyophilized powder must be reconstituted prior to injection. The required diluents are 0.5% Procaine solution (for pain relief), 0.9% Sodium Chloride solution, or sterile water for injection.
Dosing Frequency	The injection is administered once daily (QD). The standard duration for a course of treatment is 10 days of consecutive daily injections.
Age-Group Rules	Dosing is adjusted by patient size. Pediatric patients weighing less than 20 kg typically receive a lower dose (e.g., 0.5 mg/kg body weight), while those over 20 kg generally receive the adult dose (e.g., 10 mg), as determined by a physician.
Timing & Missed Dose	Administration should occur once daily, preferably at the same time each day to maintain consistency. Specific official instructions on managing a missed dose (e.g., whether to skip or administer late) should be followed as detailed by the prescribing professional.

---

Procedural Steps

The required sequence involves reconstituting the powder, drawing the solution, and administering the injection. The process of reconstitution is critical: the specified amount of sterile diluent must be added to the vial, and the contents gently mixed until the powder is fully dissolved before being drawn up for the intramuscular injection.

Evidence for use in Chronic Cerebral Ischemia and Dyscirculatory Encephalopathy

Research exploring the use of this medicine in adults with chronic cerebral ischemia (CCI) has included randomized controlled trials (RCTs) and various multicenter clinical studies. These studies primarily examined middle-aged and older adults, monitoring functional neurological deficits, cognitive scores (e.g., attention and memory), and emotional status. Studies reported patterns observed in changes to these measures, including patients with post-COVID syndrome presenting with fatigue symptoms. The certainty of the findings in this area remains low. Key limitations noted include a limited number of eligible high-quality RCTs and multiple concerns regarding risk of bias.

Evidence for use in Pediatric Cognitive and Neurofunctional Disorders

Studies have explored pediatric populations, predominantly children aged three to seven years, diagnosed with conditions such as developmental speech delay (DSD) and asthenoneurotic syndrome. Research evaluated age-appropriate cognitive function and psychomotor skill restoration. Clinical reports documented observed changes measured during the study period, including patterns related to reported measurements of change in active vocabulary volume in children with DSD. The certainty of evidence for these pediatric findings remains low, relying mainly on specific regional study contexts.

Long-term Follow-up and Research Limitations

The majority of research focuses on short-term symptom changes; follow-up durations were typically limited (10–30 days). Consequently, long-term effects are not fully established, and the durability of any observed functional changes is not well characterized by existing evidence. While older adults and specific pediatric groups have been studied, data for certain groups remain insufficient, and findings regarding complex patient profiles are generally uncertain. The overall evidence quality varies across studies, and the certainty remains low for the evidence supporting the use of this class of medicine.

Common questions about Кортексин (FAQ)

Q: Кортексин — это антибиотик или что-то другое?

Regulatory documents define Кортексин as a neuroprotector and nootropic drug. It is classified as a biological preparation of low-molecular water-soluble polypeptide fractions and is not categorized as an antibiotic.

Q: Как долго обычно нужно проходить курс лечения Кортексином?

Official administration guidelines state that a standard course of treatment involves injections administered once daily for 10 consecutive days. Questions regarding repeating the course or long-term therapeutic planning are best addressed by consulting the prescribing healthcare provider.

Q: Правда ли, что Кортексин улучшает память?

Studies have noted that the medicine was examined in relation to cerebral cognitive functions, which includes monitoring measures of memory. Research summaries from specific contexts indicate that the certainty of the findings is low and does not establish specific outcome claims regarding memory.

Q: Что делать, если пропустил укол Кортексина?

Official administration instructions confirm the medicine should be given once daily, preferably at the same time each day for consistency. Specific guidance on managing a missed dose (for example, whether to skip the dose or administer it late) is determined by the healthcare professional who prescribed the treatment.

Q: Считается ли Кортексин 'тяжелым' препаратом?

The safety profile for the medicine is informed by official regulatory classifications. All documented adverse reactions are classified as Very Rare, meaning they are expected to occur in less than 1 out of every 10,000 users. This classification provides context for the established safety data.

Q: Влияет ли прием Кортексина на артериальное давление?

The official safety profile lists Cardiac Disorders (disorders of the heart) as a category of adverse reactions, including effects like tachycardia (fast heart rate) and arrhythmia (irregular heart rhythm). However, the regulatory documents do not specifically mention effects on arterial blood pressure itself.

Q: В чем разница между Кортексином и другими пептидными препаратами?

Кортексин is officially defined as a multicomponent peptide drug. Its distinction lies in its composition: it is a unique biological preparation of low-molecular water-soluble polypeptide fractions derived from the cerebral cortex of animals, which differentiates it from synthetic chemicals or other peptide medicines.

Q: Почему инъекции Кортексина могут быть болезненными?

Official administration guidelines acknowledge that the injection may cause discomfort. For this reason, the use of a 0.5% Procaine solution is specifically listed as an allowed diluent for pain relief during the reconstitution of the powder. Additionally, injection site reactions are listed among the possible side effects.

Q: Может ли Кортексин взаимодействовать с витаминами или БАДами?

Official regulatory data states that there are no documented conflicts related to metabolism with other medicinal products. Furthermore, the regulatory data does not document specific interactions with food, alcohol, herbal products, or other dietary supplements.

Q: Используется ли Кортексин при задержке речевого развития у детей?

Research has explored pediatric populations, such as children diagnosed with developmental speech delay (DSD). These studies evaluated changes in age-appropriate cognitive function and psychomotor skills. Research summaries indicate that the certainty of the evidence for this specific context remains low.

Q: Есть ли противопоказания, о которых часто забывают?

The main contraindications are hypersensitivity, pregnancy, and lactation. However, a critical procedural constraint applies to children: the use of Lidocaine (Procaine) as a solvent is not recommended in this population. This restriction is documented because using Lidocaine for reconstitution in children is officially associated with an increased severity of adverse reactions.

Q: Имеет ли Кортексин регистрацию в других странах, кроме России?

The medicine is officially registered with regulatory bodies in the Russian Federation and other CIS countries. The official product labeling does not document registration status in territories such as the United States (FDA) or European Union (EMA).

Q: Влияет ли время суток на эффективность инъекций Кортексина?

The official guidelines require the injection to be administered once daily. To ensure consistency throughout the course of treatment, it is recommended to administer the dose preferably at the same time each day. The official document does not provide data specifying differences in effectiveness based on administration time (e.g., morning versus evening).

Q: Могут ли быть индивидуальные реакции на Кортексин, не описанные в инструкции?

The official safety profile is based on adverse reactions that have been formally documented in clinical use and classified as Very Rare. While official documents list the established safety data, they cannot definitively cover every possible individual patient response.

Q: Есть ли разница между Кортексином 5 мг и 10 мг?

The different available strengths are intended to manage age-based and weight-based dosing as determined by a healthcare provider. For example, official guidelines note that pediatric patients weighing less than 20 kg typically require a lower, weight-adjusted dose, while those over 20 kg generally receive the adult dose.

Q: Связан ли прием Кортексина с изменением настроения?

Official documents list certain effects under Nervous System Disorders, such as somnolence (drowsiness) and insomnia (difficulty sleeping). Furthermore, some research evidence mentions the monitoring of a patient’s emotional status during treatment. Specific changes to 'mood' are not explicitly listed among the official adverse reactions.

Q: Какие ощущения могут возникнуть сразу после укола?

Officially documented side effects include possible reactions at the injection site. To help mitigate potential pain, the administration guidelines recommend using Procaine solution as the diluent during preparation. If severe reactions occur, consulting a healthcare professional is recommended.

Official Storage and Disposal Requirements

Storage and disposal requirements for Кортексин (Cortexin) are defined by the regulatory documentation of its country of licensing. The product, supplied as a lyophilisate of polypeptide fractions, requires specific environmental control to maintain stability.

Requirement Type	Official Labeled Condition
Temperature Constraint	Store at a temperature not exceeding 25°C (do not freeze).
Environmental Protection	Store in a dry, dark place and protect from light.
Packaging	Must be kept in its original container.
Child Safety	Keep out of the sight and reach of children.

Unused or expired product must be disposed of in accordance with local pharmaceutical waste regulations. The medicine must not be discarded into household wastewater or regular trash.